Thursday, November 21, 2024 11/21/2024

Development of novel protein-based vaccine formulations to prevent pneumococcal colonization and disease

Award Number: R21AI148722
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Project Summary/Abstract One of the major problems of the great burden of Streptococcus pneumoniae infections is the acquisition of antimicrobial resistance and the global spread of resistant clones. This problems get enhanced by the major disadvantages of the current capsular polysaccharide based vaccines, such as cost, serotype specificity, and the resulting incomplete coverage. While the use of polysaccharide vaccines, specially the conjugate vaccine, had significantly reduced the amount of invasive disease caused Spn, it only has reduced that of the represented serotypes. This occurs mainly because of disease being caused by serotypes not present in the vaccine (maximum of 23 of the >97 capsule types, only 13 in the conjugate vaccine) and replacement carriage. Our rationale is that development of a subunit based vaccine utilizing novel conserved antigenic proteins in conjunction with novel polyphosphazene (PPZ) adjuvants, proven to induce adaptive immunity will deepen the current toolkit to prevent pneumococcal disease without serotype limitations. Thus, we hypothesize that addition of conserved immunogenic proteins to the PPZ molecule will provide the groundwork for the development of a broadly protective pneumococcal subunit based vaccine. The gaps in knowledge we aim to bridge are to define and characterize novel pneumococcal antigenic proteins and polyelectrolyte adjuvants formulations that will initiate adaptive immune responses and lead to protection against disease in a serotype independent manner. The proposed work is significant due to the high incidence serotype replacement that current polysaccharide based vaccines are prone to, which leads to increase susceptibility of children and the elderly to Spn carriage and severe infections (e.g. pneumonia, bacteremia, and meningitis); and innovative since it will use novel formulations of antigenic and conserved pneumococcal proteins to induce potent adaptive immune responses, that will not be serotype dependent.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	J. CRAIG VENTER INSTITUTE, INC.	4120 CAPRICORN LN	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	2	8/10/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $283,588 )
2021	2021	J. CRAIG VENTER INSTITUTE, INC.	4120 CAPRICORN LN	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	2	7/29/2021	NON-COMPETING CONTINUATION	$283,588
														Subtotal = $283,588

Issue Date FY: 2020 ( Subtotal = $258,588 )
2020	2020	J. CRAIG VENTER INSTITUTE, INC.	4120 CAPRICORN LN	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	1	9/15/2020	NEW	$258,588
														Subtotal = $258,588

Grand Total All Awards = $542,176

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of novel protein-based vaccine formulations to prevent pneumococcal colonization and disease

Award Number: R21AI148722

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer